

BRR Media Interview with CEO Sarah Howell



Areacor, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, is pleased to announce that the Company has filed a Clinical Trial Application to conduct a Phase I study in Type 1 patients of its ultra-rapid acting insulin product, AT247. This novel formulation of prandial insulin is designed to deliver an acceleration of insulin absorption post injection.

Listen to the interview here:

<https://www.brrmedia.co.uk/broadcasts/5c33760bbf0ed0763229072a/arecor-phase-1-clinical-trial>